Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 4/2020

Open Access 01-04-2020 | Antidepressant Drugs | Review Article

Psychotropic Drug-Associated Pneumonia in Older Adults

Authors: Blair Rajamaki, Sirpa Hartikainen, Anna-Maija Tolppanen

Published in: Drugs & Aging | Issue 4/2020

Login to get access

Abstract

The use of psychotropic drugs (antipsychotics, benzodiazepines and benzodiazepine-related drugs, and antidepressants) is common, with a prevalence estimates range of 19–29% among community dwelling older adults. These drugs are often prescribed for off-label use, including neuropsychiatric symptoms. The older adult population also has high rates of pneumonia and some of these cases may be associated with adverse drug events. In this narrative review, we summarize the findings from current observational studies on the association between psychotropic drug use and pneumonia in older adults. In addition to studies assessing the use of psychotropics, we included antiepileptic drugs, as they are also central nervous system-acting drugs, whose use is becoming more common in the aging population. The use of antipsychotics, benzodiazepine, and benzodiazepine-related drugs are associated with increased risk of pneumonia in older adults (≥ 65 years of age), and these findings are not limited to this age group. Minimal and conflicting evidence has been reported on the association between antidepressant drug use and pneumonia, but differences between study populations make it difficult to compare findings. Studies regarding antiepileptic drug use and risk of pneumonia in older persons are lacking, although an increased risk of pneumonia in antiepileptic drug users compared with non-users in persons with Alzheimer’s disease has been reported. Tools such as the American Geriatric Society Beers Criteria and the STOPP/START criteria for potentially inappropriate medications aids prescribers to avoid these drugs in order to reduce the risk of adverse drug events. However, risk of pneumonia is not mentioned in the current criteria and more research on this topic is needed, especially in vulnerable populations, such as persons with dementia.
Literature
1.
2.
Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988–2002. JAMA. 2005;294:2712–9.CrossRefPubMed
3.
Heron M. Deaths: leading causes for 2017. Natl Vital Stat Rep-US Dep Health Hum Serv. 2019;68:1–77.
4.
Curns AT, Holman RC, Sejvar JJ, Owings MF, Schonberger LB. Infectious disease hospitalizations among older adults in the United States from 1990 through 2002. JAMA Intern Med. 2005;165:2514–20.CrossRef
5.
Centers for Disease Control. QuickStats: rate* of hospitalization for pneumonia, by age group—National Hospital Discharge Survey, United States, 2000–2010. 2012.
6.
Van Gageldonk-Lafeber AB, Bogaerts MAH, Verheij RA, Van Der Sande MAB. Time trends in primary-care morbidity, hospitalization and mortality due to pneumonia. Epidemiol Infect. 2009;137:1472–8.CrossRefPubMed
7.
8.
Søgaard M, Nielsen RB, Schønheyder HC, Nørgaard M, Thomsen RW. Nationwide trends in pneumonia hospitalization rates and mortality, Denmark 1997–2011. Respir Med. 2014;108:1214–22.CrossRefPubMed
9.
Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642–50.CrossRefPubMed
10.
Ochoa-Gondar O, Vila-Córcoles A, de Diego C, Arija V, Maxenchs M, Grive M, et al. The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 Study. BMC Public Health. 2008;8:222.CrossRefPubMedPubMedCentral
11.
Baik I, Curhan GC, Rimm EB, Bendich A, Willett WC, Fawzi WW. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch Intern Med. 2000;160:3082–8.CrossRefPubMed
12.
13.
Marrie TJ, Huang JQ. Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study. Can Respir J. 2005;12:139–42.CrossRefPubMed
14.
Järvinen H, Taipale H, Koponen M, Tanskanen A, Tiihonen J, Tolppanen A-M, et al. Hospitalization after oral antibiotic initiation in finnish community dwellers with and without Alzheimer’s disease: retrospective register-based cohort study. J Alzheimers Dis. 2018;64:437–45.CrossRefPubMed
15.
Liapikou A, Cilloniz C, Torres A. Drugs that increase the risk of community-acquired pneumonia: a narrative review. Expert Opin Drug Saf. 2018;17:991–1003.CrossRefPubMed
16.
Tolppanen A-M, Koponen M, Tanskanen A, Lavikainen P, Sund R, Tiihonen J, et al. Antipsychotic use and risk of hospitalization or death due to pneumonia in persons with and those without alzheimer disease. Chest. 2016;150:1233–41.CrossRefPubMed
17.
Taipale H, Tolppanen A-M, Koponen M, Tanskanen A, Lavikainen P, Sund R, et al. Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease. CMAJ Can Med Assoc J J Assoc Med Can. 2017;189:E519–29.CrossRef
18.
World Health Organization. The world health report 2001: Mental health: new understanding. New Hope: World Health Organization; 2001.
19.
World Health Organization. Neurological disorders: public health challenges. Geneva: World Health Organization; 2006.
20.
21.
22.
Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Sætre E, et al. Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: a pharmacoepidemiological study of CNS-active drugs in Norway, 2004–2015. Epilepsy Res. 2018;139:35–42.CrossRefPubMed
23.
Taipale H, Lampela P, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, et al. Antiepileptic drug use is associated with an increased risk of pneumonia among community-dwelling persons with Alzheimer’s disease-matched cohort study. J Alzheimers Dis. 2019;68:127–36.CrossRefPubMedPubMedCentral
24.
Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc. 2003;51:671–7.CrossRefPubMed
25.
Linjakumpu T, Hartikainen S, Klaukka T, Koponen H, Kivelä S-L, Isoaho R. Psychotropics among the home-dwelling elderly—increasing trends. Int J Geriatr Psychiatry. 2002;17:874–83.CrossRefPubMed
26.
Voyer P, Cohen D, Lauzon S, Collin J. Factors associated with psychotropic drug use among community-dwelling older persons: a review of empirical studies. BMC Nurs. 2004;3:3.CrossRefPubMedPubMedCentral
27.
Téllez-Lapeira J, López-Torres Hidalgo J, García-Agua Soler N, Gálvez-Alcaraz L, Escobar-Rabadán F, García-Ruiz A. Prevalence of psychotropic medication use and associated factors in the elderly. Eur J Psychiatry. 2016;30:183–94.
28.
Taipale H, Koponen M, Tanskanen A, Tolppanen A-M, Tiihonen J, Hartikainen S. High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort. Eur Neuropsychopharmacol. 2014;24:1729–37.CrossRefPubMed
29.
Gustafsson M, Karlsson S, Gustafson Y, Lövheim H. Psychotropic drug use among people with dementia–a six-month follow-up study. BMC Pharmacol Toxicol. 2013;14:56.CrossRefPubMedPubMedCentral
30.
Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;2016(12):459–509.CrossRef
31.
Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment results from the cardiovascular health study. JAMA. 2002;288:1475–83.CrossRefPubMed
32.
Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173:543–6.CrossRefPubMed
33.
Beijer HJM, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci PWS. 2002;24:46–54.CrossRefPubMed
34.
Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J. 2001;31:199–205.CrossRefPubMed
35.
Page RL, Mark RJ. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. Am J Geriatr Pharmacother. 2006;4:297–305.CrossRefPubMed
36.
Morin L, Laroche M-L, Texier G, Johnell K. Prevalence of potentially inappropriate medication use in older adults living in nursing homes: a systematic review. J Am Med Dir Assoc. 2016;17:862.e1–9.CrossRef
37.
38.
Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet Lond Engl. 2007;370:173–84.CrossRef
39.
2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;2019(67):674–94.CrossRef
40.
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.CrossRefPubMed
41.
Maguire A, Hughes C, Cardwell C, O’Reilly D. Psychotropic medications and the transition into care: a national data linkage study. J Am Geriatr Soc. 2013;61:215–21.CrossRefPubMed
42.
Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, et al. Trends in antipsychotic use in dementia 1999–2007. JAMA Psychiatry. 2011;68:190–7.
43.
Moga DC, Taipale H, Tolppanen A-M, Tanskanen A, Tiihonen J, Hartikainen S, et al. A comparison of sex differences in psychotropic medication use in older people with Alzheimer’s disease in the US and Finland. Drugs Aging. 2017;34:55–65.CrossRefPubMedPubMedCentral
44.
45.
46.
47.
Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res. 2001;35:187–91.CrossRefPubMed
48.
49.
50.
51.
Herzig SJ, Rothberg MB, Guess JR, Gurwitz JH, Marcantonio ER. Antipsychotic medication utilization in nonpsychiatric hospitalizations. J Hosp Med. 2016;11:543–9.CrossRefPubMed
52.
Herzig SJ, Rothberg MB, Guess JR, Stevens JP, Marshall J, Gurwitz JH, et al. Antipsychotic use in hospitalized adults: rates, indications, and predictors. J Am Geriatr Soc. 2016;64:299–305.CrossRefPubMedPubMedCentral
53.
Loh KP, Ramdass S, Garb JL, Brennan MJ, Lindenauer PK, Lagu T. From hospital to community: use of antipsychotics in hospitalized elders. J Hosp Med. 2014;9:802–4.CrossRefPubMed
54.
55.
Kuroda N, Hamada S, Sakata N, Jeon B, Iijima K, Yoshie S, et al. Antipsychotic use and related factors among people with dementia aged 75 years or older in Japan: a comprehensive population-based estimation using medical and long-term care data. Int J Geriatr Psychiatry. 2019;34:472–9.CrossRefPubMed
56.
Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer’s disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013;3:e002080.CrossRefPubMedPubMedCentral
57.
Gallini A, Andrieu S, Donohue JM, Oumouhou N, Lapeyre-Mestre M, Gardette V. Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2014;24:95–104.CrossRef
58.
Sultana J, Fontana A, Giorgianni F, Pasqua A, Cricelli C, Spina E, et al. The effect of safety warnings on antipsychotic drug prescribing in elderly persons with dementia in the United Kingdom and Italy: a population-based study. CNS Drugs. 2016;30:1097–109.CrossRefPubMed
59.
60.
Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72:136–42.CrossRefPubMed
61.
López-Muñoz F, Álamo C, García-García P. The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: half a century of anxiolytic drugs. J Anxiety Disord. 2011;25:554–62.CrossRefPubMed
62.
63.
Ancoli-Israel S. Sleep and its disorders in aging populations. Art Good Sleep Proc 6th Int Sleep Disord Forum Sleep Soc. 2009;10:7–11.
64.
Islam MM, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen P-A, et al. Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology. 2016;47:181–91.CrossRefPubMed
65.
Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing. 2010;40:23–9.CrossRefPubMed
66.
Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Sáez de Adana E, Cano AI, Martínez-Cengotitabengoa MT, Besga A, et al. Relationship between the use of benzodiazepines and falls in older adults: a systematic review. Maturitas. 2017;101:17–22.CrossRefPubMed
67.
Saarelainen L, Tolppanen A-M, Koponen M, Tanskanen A, Sund R, Tiihonen J, et al. Risk of hip fracture in benzodiazepine users with and without Alzheimer disease. J Am Med Dir Assoc. 2017;18:87.e15–21.CrossRef
68.
Donnelly K, Bracchi R, Hewitt J, Routledge PA, Carter B. Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis. PLoS One. 2017;12:e0174730.CrossRefPubMedPubMedCentral
69.
Hemmelgarn B, Suissa S, Huang A, Jean-Francois B, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278:27–31.CrossRefPubMed
70.
Brandt J, Leong C. Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs RD. 2017;17:493–507.CrossRef
71.
72.
Picton JD, Marino AB, Nealy KL. Benzodiazepine use and cognitive decline in the elderly. Am J Health Syst Pharm. 2018;75:e6–12.CrossRefPubMed
73.
Béland S-G, Préville M, Dubois M-F, Lorrain D, Grenier S, Voyer P, et al. Benzodiazepine use and quality of sleep in the community-dwelling elderly population. Aging Ment Health. 2010;14:843–50.CrossRefPubMed
74.
Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. J Am Geriatr Soc. 2011;59:1899–907.CrossRefPubMedPubMedCentral
75.
Petrov ME, Sawyer P, Kennedy R, Bradley LA, Allman RM. Benzodiazepine (BZD) use in community-dwelling older adults: longitudinal associations with mobility, functioning, and pain. Arch Gerontol Geriatr. 2014;59:331–7.CrossRefPubMedPubMedCentral
76.
Brett J, Maust DT, Bouck Z, Ignacio RV, Mecredy G, Kerr EA, et al. Benzodiazepine use in older adults in the United States, Ontario, and Australia from 2010 to 2016. J Am Geriatr Soc. 2018;66:1180–5.CrossRefPubMedPubMedCentral
77.
Ster MP, Gorup EC. Psychotropic medication use among elderly nursing home residents in Slovenia: cross-sectional study. Croat Med J. 2011;52:16–24.CrossRef
78.
Azermai M, Elseviers M, Petrovic M, Van Bortel L, Stichele RV. Geriatric drug utilisation of psychotropics in Belgian nursing homes. Hum Psychopharmacol Clin Exp. 2011;26:12–20.CrossRef
79.
Bourgeois J, Elseviers MM, Azermai M, Van Bortel L, Petrovic M, Vander Stichele RR. Benzodiazepine use in Belgian nursing homes: a closer look into indications and dosages. Eur J Clin Pharmacol. 2012;68:833–44.CrossRefPubMed
80.
Gobert M, D’hoore W. Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the French-speaking area of Switzerland. Int J Geriatr Psychiatry. 2005;20:712–21.CrossRefPubMed
81.
Hosia-Randell H, Pitkälä K. Use of psychotropic drugs in elderly nursing home residents with and without dementia in Helsinki, Finland. Drugs Aging. 2005;22:793–800.CrossRefPubMed
82.
Maust DT, Kales HC, Wiechers IR, Blow FC, Olfson M. No end in sight: benzodiazepine use in older adults in the United States. J Am Geriatr Soc. 2016;64:2546–53.CrossRefPubMedPubMedCentral
83.
84.
Gardarsdottir H, Heerdink ER, van Dijk L, Egberts ACG. Indications for antidepressant drug prescribing in general practice in the Netherlands. J Affect Disord. 2007;98:109–15.CrossRefPubMed
85.
86.
Pittenger C, Kelmendi B, Bloch M, Krystal JH, Coric V. Clinical treatment of obsessive compulsive disorder. Psychiatry Edgmont Pa Townsh. 2005;2:34–43.
87.
Sansone RA, Sansone LA. Pain, pain, go away: antidepressants and pain management. Psychiatry Edgmont Pa Townsh. 2008;5:16–9.
88.
89.
Mottram PG, Wilson K, Strobl JJ. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006;1–58.
90.
91.
92.
93.
Riedel WJ, van Praag HM. Avoiding and managing anticholinergic effects of antidepressants. CNS Drugs. 1995;3:245–59.CrossRef
94.
95.
96.
97.
Chatterjee S, Carnahan RM, Chen H, Holmes HM, Johnson ML, Aparasu RR. Anticholinergic medication use and risk of pneumonia in elderly adults: a nested case–control study. J Am Geriatr Soc. 2016;64:394–400.CrossRefPubMed
98.
Bourgeois J, Elseviers MM, Van Bortel L, Petrovic M, Vander Stichele RH. The use of antidepressants in Belgian nursing homes. Drugs Aging. 2012;29:759–69.CrossRefPubMed
99.
Kramer D, Allgaier A-K, Fejtkova S, Mergl R, Hegerl U. Depression in nursing homes: prevalence, recognition, and treatment. Int J Psychiatry Med. 2009;39:345–58.CrossRefPubMed
100.
Puranen A, Taipale H, Koponen M, Tanskanen A, Tolppanen A-M, Tiihonen J, et al. Incidence of antidepressant use in community-dwelling persons with and without Alzheimer’s disease: 13-year follow-up. Int J Geriatr Psychiatry. 2017;32:94–101.CrossRefPubMed
101.
Tamblyn R, Bates DW, Buckeridge DL, Dixon W, Forster AJ, Girard N, et al. Multinational comparison of new antidepressant use in older adults: a cohort study. BMJ Open. 2019;9:e027663.CrossRefPubMedPubMedCentral
102.
103.
104.
Masopust J, Protopopova D, Valis M, Pavelek Z, Klimova B. Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: A review. 2018.
105.
106.
Park S-P, Kwon S-H. Cognitive effects of antiepileptic drugs. J Clin Neurol Seoul Korea. 2008;4:99–106.CrossRef
107.
108.
Loeb M, McGeer A, McArthur M, Walter S, Simor AE. Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities. Arch Intern Med. 1999;159:2058–64.CrossRefPubMed
109.
Landmark CJ, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders—a population-based study of prescriptions. Epilepsy Res. 2009;87:31–9.CrossRef
110.
Savica R, Beghi E, Mazzaglia G, Innocenti F, Brignoli O, Cricelli C, et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000–2005. Eur J Neurol. 2007;14:1317–21.CrossRefPubMed
111.
Alacqua M, Trifirò G, Spina E, Moretti S, Tari DU, Bramanti P, et al. Newer and older antiepileptic drug use in Southern Italy: a population-based study during the years 2003–2005. Epilepsy Res. 2009;85:107–13.CrossRefPubMed
112.
Hollingworth SA, Eadie MJ. Antiepileptic drugs in Australia: 2002–2007. Pharmacoepidemiol Drug Saf. 2010;19:82–9.CrossRefPubMed
113.
114.
Tsiropoulos I, Gichangi A, Andersen M, Bjerrum L, Gaist D, Hallas J. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand. 2006;113:405–11.CrossRefPubMed
115.
Sarycheva T, Taipale H, Lavikainen P, Tiihonen J, Tanskanen A, Hartikainen S, et al. Incidence and prevalence of antiepileptic medication use in community-dwelling persons with and without Alzheimer’s disease. J Alzheimers Dis. 2018;66:387–95.CrossRefPubMedPubMedCentral
116.
Garrard J, Harms S, Hardie N, Eberly LE, Nitz N, Bland P, et al. Antiepileptic drug use in nursing home admissions. Ann Neurol. 2003;54:75–85.CrossRefPubMed
117.
Garrard J, Cloyd J, Gross C, Hardie N, Thomas L, Lackner T, et al. Factors associated with antiepileptic drug use among elderly nursing home residents. J Gerontol Ser A. 2000;55:M384–92.CrossRef
118.
Bathena SPR, Leppik IE, Kanner AM, Birnbaum AK. Antiseizure, antidepressant, and antipsychotic medication prescribing in elderly nursing home residents. Epilepsy Behav EB. 2017;69:116–20.CrossRef
119.
Huying F, Klimpe S, Werhahn KJ. Antiepileptic drug use in nursing home residents: a cross-sectional, regional study. Seizure Eur J Epilepsy. 2006;15:194–7.CrossRef
120.
Ishii H, Kushima H, Kinoshita Y, Matsumoto T, Watanabe K, Fujita M. The limited impact of psychiatric disease and psychotropic medication on the outcome of hospitalization for pneumonia. J Infect Chemother Off J Jpn Soc Chemother. 2018;24:1009–12.CrossRef
121.
Dzahini O, Singh N, Taylor D, Haddad P. Antipsychotic drug use and pneumonia: systematic review and meta-analysis. J Psychopharmacol (Oxf). 2018;32:1167–81.CrossRef
122.
Herzig SJ, LaSalvia MT, Naidus E, Rothberg MB, Zhou W, Gurwitz JH, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. J Am Geriatr Soc. 2017;65:2580–6.CrossRefPubMedPubMedCentral
123.
Kim DH, Huybrechts KF, Patorno E, Marcantonio ER, Park Y, Levin R, et al. Adverse events associated with antipsychotic use in hospitalized older adults after cardiac surgery. J Am Geriatr Soc. 2017;65:1229–37.CrossRefPubMedPubMedCentral
124.
Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med. 2014;161:242–8.CrossRefPubMed
125.
Hennessy S, Bilker WB, Leonard CE, Chittams J, Palumbo CM, Karlawish JH, et al. Observed association between antidepressant use and pneumonia risk was confounded by comorbidity measures. J Clin Epidemiol. 2007;60:911–8.CrossRefPubMedPubMedCentral
126.
Sun Q, Zhang L, Wu Z, Hu D. Benzodiazepines or related drugs and risk of pneumonia: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2019;34:513–21.CrossRefPubMed
127.
Chung W-S, Lai C-Y, Lin C-L, Kao C-H. Adverse respiratory events associated with hypnotics use in patients of chronic obstructive pulmonary disease: a population-based case–control study. Medicine (Baltimore). 2015;94:e1110.CrossRefPubMedPubMedCentral
128.
Wang M-T, Wang Y-H, Chang H-A, Tsai C-L, Yang Y-S, Lin CW, et al. Benzodiazepine and Z-drug use and risk of pneumonia in patients with chronic kidney disease: a population-based nested case–control study. PLoS One. 2017;12:e0179472.CrossRefPubMedPubMedCentral
129.
Vozoris NT, Fischer HD, Wang X, Stephenson AL, Gershon AS, Gruneir A, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2014;44:332–40.CrossRefPubMed
130.
Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ Can Med Assoc J J Assoc Medicale Can. 2011;183:E411–9.CrossRef
131.
Vozoris NT, Wang X, Austin PC, Stephenson AL, O’Donnell DE, Gershon AS, et al. Serotonergic antidepressant use and morbidity and mortality among older adults with COPD. Eur Respir J. 2018;52:1800475.CrossRefPubMed
132.
133.
Gambassi G, Sultana J, Trifirò G. Antipsychotic use in elderly patients and the risk of pneumonia. Expert Opin Drug Saf. 2015;14:1–6.CrossRefPubMed
134.
Nosè M, Recla E, Trifirò G, Barbui C. Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2015;24:812–20.CrossRefPubMed
135.
136.
137.
138.
Trifirò G, Gambassi G, Sen EF, Caputi AP, Bagnardi V, Brea J, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case–control study. Ann Intern Med. 2010;152(418–25):W139–40.
139.
Pollmächer T, Haack M, Schuld A, Kraus T, Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res. 2000;34:369–82.CrossRefPubMed
140.
141.
Trifirò G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab. 2011;12:611–20.CrossRefPubMed
142.
Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case–control and survival analysis in a population-based cohort. Thorax. 2013;68:163–70.CrossRefPubMed
143.
Tune L. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;11–4.
144.
145.
146.
147.
148.
149.
150.
Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85:270–88.CrossRefPubMed
151.
Pellegrino TC, Bayer BM. Specific serotonin reuptake inhibitor-induced decreases in lymphocyte activity require endogenous serotonin release. NeuroImmunoModulation. 2000;8:179–87.CrossRefPubMed
152.
Fazzino F, Montes C, Urbina M, Carreira I, Lima L. Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation. J Neuroimmunol. 2008;196:173–80.CrossRefPubMed
153.
Taler M, Gil-Ad I, Lomnitski L, Korov I, Baharav E, Bar M, et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007;17:774–80.CrossRefPubMed
154.
Shenoy AR, Dehmel T, Stettner M, Kremer D, Kieseier BC, Hartung HP, et al. Citalopram suppresses thymocyte cytokine production. J Neuroimmunol. 2013;262:46–52.CrossRefPubMed
155.
Godhwani N, Bahna SL. Antiepilepsy drugs and the immune system. Ann Allergy Asthma Immunol. 2016;117:634–40.CrossRefPubMed
156.
Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112:228–42.CrossRefPubMed
157.
Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc. 2007;55:S373–82.CrossRefPubMed
158.
Crotty M, Halbert J, Rowett D, Giles L, Birks R, Williams H, et al. An outreach geriatric medication advisory service in residential aged care: a randomised controlled trial of case conferencing. Age Ageing. 2004;33:612–7.CrossRefPubMed
159.
Yang S-Y, Liao Y-T, Liu H-C, Chen WJ, Chen C-C, Kuo C-J. Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study. J Clin Psychiatry. 2013;74:e79–86.CrossRefPubMed
160.
161.
Tong S, Amand C, Kieffer A, Kyaw MH. Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008–2014. BMC Health Serv Res. 2018;18:715.CrossRefPubMedPubMedCentral
162.
Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009;103:309–16.CrossRefPubMed
163.
Singh RR, Nayak R. Impact of FDA black box warning on psychotropic drug use in noninstitutionalized elderly patients diagnosed with dementia: a retrospective study. J Pharm Pract. 2015;29:495–502.CrossRefPubMed
164.
Brown JD, Hutchison LC, Li C, Painter JT, Martin BC. Predictive Validity of the beers and screening tool of older persons’ potentially inappropriate prescriptions (STOPP) criteria to detect adverse drug events, hospitalizations, and emergency department visits in the united states. J Am Geriatr Soc. 2016;64:22–30.CrossRefPubMedPubMedCentral
165.
Pazan F, Weiss C, Wehling M, FORTA. The EURO-FORTA (Fit fOR The Aged) List: international consensus validation of a clinical tool for improved drug treatment in older people. Drugs Aging. 2018;35:61–71.
166.
Albert SM, Colombi A, Hanlon J. Potentially inappropriate medications and risk of hospitalization in retirees: analysis of a US retiree health claims database. Drugs Aging. 2010;27:407–15.CrossRefPubMedPubMedCentral
167.
Dedhiya SD, Hancock E, Craig BA, Doebbeling CC, Thomas J. Incident use and outcomes associated with potentially inappropriate medication use in older adults. Am J Geriatr Pharmacother. 2010;8:562–70.CrossRefPubMed
168.
Price SD, Holman CDJ, Sanfilippo FM, Emery JD. Association between potentially inappropriate medications from the beers criteria and the risk of unplanned hospitalization in elderly patients. Ann Pharmacother. 2014;48:6–16.CrossRefPubMed
169.
Fialová D, Topinková E, Gambassi G, Finne-Soveri H, Jónsson PV, Carpenter I, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005;293:1348–58.CrossRefPubMed
170.
Pasina L, Djade CD, Tettamanti M, Franchi C, Salerno F, Corrao S, et al. Prevalence of potentially inappropriate medications and risk of adverse clinical outcome in a cohort of hospitalized elderly patients: results from the REPOSI Study. J Clin Pharm Ther. 2014;39:511–5.CrossRefPubMed
171.
Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71:861–75.CrossRefPubMedPubMedCentral
172.
173.
Rognstad S, Brekke M, Fetveit A, Spigset O, Wyller TB, Straand J. The Norwegian General Practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients. A modified Delphi study. Scand J Prim Health Care. 2009;27:153–9.
174.
Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415–27.
175.
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–602.
176.
Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:655–79.CrossRefPubMed
177.
178.
Harris T, Carey IM, Shah SM, DeWilde S, Cook DG. Antidepressant prescribing in older primary care patients in community and care home settings in England and Wales. J Am Med Dir Assoc. 2012;13:41–7.CrossRefPubMed
179.
Azermai M, Petrovic M, Elseviers MM, Bourgeois J, Van Bortel LM, Vander Stichele RH. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Res Rev. 2012;11:78–86.CrossRefPubMed
180.
Zuidema SU, Johansson A, Selbaek G, Murray M, Burns A, Ballard C, et al. A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice. Int Psychogeriatr. 2015;27:1849–59.CrossRefPubMedPubMedCentral
181.
Jackson JW, VanderWeele TJ, Blacker D, Schneeweiss S. Mediators of first- versus second-generation antipsychotic-related mortality in older adults. Epidemiol Camb Mass. 2015;26:700–9.CrossRef
182.
Aparasu RR, Chatterjee S, Chen H. Risk of pneumonia in elderly nursing home residents using typical versus atypical antipsychotics. Ann Pharmacother. 2013;47:464–74.CrossRefPubMed
183.
Huybrechts KF, Schneeweiss S, Gerhard T, Olfson M, Avorn J, Levin R, et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc. 2012;60:420–9.CrossRefPubMedPubMedCentral
184.
Wang PS, Schneeweiss S, Setoguchi S, Patrick A, Avorn J, Mogun H, et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007;27:707–10.CrossRefPubMed
185.
Mehta S, Pulungan Z, Jones BT, Teigland C. Comparative safety of atypical antipsychotics and the risk of pneumonia in the elderly. Pharmacoepidemiol Drug Saf. 2015;24:1271–80.CrossRefPubMed
186.
187.
Knol W, van Marum RJ, Jansen PAF, Souverein PC, Schobben AFAM, Egberts ACG. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56:661–6.CrossRefPubMed
188.
Pratt N, Roughead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Saf. 2011;34:567–75.CrossRefPubMed
189.
Star K, Bate A, Meyboom RH, Edwards IR. Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern? Br J Gen Pract J R Coll Gen Pract. 2010;60:e385–94.CrossRef
190.
Taipale H, Tolppanen A-M, Koponen M, Tanskanen A, Lavikainen P, Sund R, et al. Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease. CMAJ Can Med Assoc J J Assoc Medicale Can. 2017;189:E519–29.CrossRef
191.
Maeda T, Babazono A, Nishi T, Yasui M. Quantification of adverse effects of regular use of triazolam on clinical outcomes for older people with insomnia: a retrospective cohort study. Int J Geriatr Psychiatry. 2016;31:186–94.CrossRefPubMed
192.
Jung S, Spence MM, Escasa NM, Lee EA, Hui RL, Gibbs NE. The risk of pneumonia in older adults using nonbenzodiazepine hypnotics. J Manag Care Spec Pharm. 2016;22:932–8.PubMed
Metadata
Title
Psychotropic Drug-Associated Pneumonia in Older Adults
Authors
Blair Rajamaki
Sirpa Hartikainen
Anna-Maija Tolppanen
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 4/2020
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-020-00754-1

Other articles of this Issue 4/2020

Drugs & Aging 4/2020 Go to the issue

Original Research Article

Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study

Review Article

Benzodiazepine Prescribing in People with Chronic Obstructive Pulmonary Disease: Clinical Considerations

Original Research Article

Prevalence and Factors Associated with Analgesic Prescribing in Poly-Medicated Elderly Patients

Original Research Article

Adverse Effects of Anticholinergic Drugs on Cognition and Mobility: Cutoff for Impairment in a Cross-Sectional Study in Young–Old and Old–Old Adults

Short Communication

Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age

Original Research Article

Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits